Abstract
In his review of recent advances in second-trimester abortion, Cassing Hammond1 did not include several specifically relevant clinical reports. In his discussion, he mentioned inadequate information in the medical literature concerning the use of misoprostol as an adjunct in second-trimester surgical abortion that includes dose and route of delivery, the effect on induction-to-abortion interval of the combination of osmotic dilators with misoprostol, the paucity of comparative studies that involve dilapan as an osmotic dilator, the lack of dose-finding studies of digoxin in the induction of fetal death in second-trimester abortion, the relative safety of second-trimester dilation and evacuation methods of abortion, the safety of various procedures for patients with multiple gestation, and the risks of uterine rupture in second-trimester abortion in the presence of a history of cesarean delivery with different treatment regimens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
